This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for Irish Healthcare Professionals. If you are not a Healthcare Professional, please click here.
Adverse event reporting information is available at the bottom of this webpage.

Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex)
Dysport<sup>®</sup> (<em>Clostridium botulinum</em> type A toxin-haemagglutinin complex)

Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) therapeutic indications

Dysport® is indicated in paediatric patients for:

  • Upper limbs in paediatric cerebral palsy patients ≥ 2 years of age.
  • Treatment of: Dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients ≥ 2 years of age.
  • Please visit the PI link at the top of this page for the full list of indications.
Spasticity in children

Spasticity in children

Spasticity is a prevalent and frequently disabling motor disorder in children with cerebral palsy.1 Cerebral palsy is the most common motor disability in childhood, leading to lifelong physical disability.2,3

Unilateral and bilateral cerebral palsy

In monoplegia, the one limb affected is more often the lower limb.3 In hemiplegia, one side of the body is affected, and the upper limb is usually more involved than the lower limb.3 In diplegia, all limbs are affected, but the lower limbs are much more affected than the upper limbs.3 Triplegia usually has unilateral upper limb and bilateral (asymmetrical) lower limb involvement. In quadriplegia, the whole body is involved.3

More than 80% of children with cerebral palsy have upper limb involvement.4 Spasticity of the upper limbs affect the ability to perfom activities of daily living, such as eating, drinking, grooming and dressing.5

Common patterns of upper limb spasticity in children4

 

Lower limb involvement leads to a tendency for the hips to be flexed and adducted with the knees flexed and in valgus, and the ankles in equinus, resulting in toe walking.6

Common patterns of lower limb spasticity in children6

 

Over time, fixed contractures develop that increase disability.7

Children with cerebral palsy have long sarcomere lengths compared with those observed during typical child development3

 

Spasticity of the lower limbs results in deformity that can affect ambulation, bed positioning, sitting, chair level activities, transfers and standing up.11

When used in conjunction with occupational therapy, Dysport® can reduce muscle spasticity and optimise the effects of therapies used for enhancing motor ability and improving functional skills.12,13

References:

  1. Tilton A, et al. J Child Neurol. 2017;32(5):482–487.
  2. Centre of Disease Control and Prevention. What is Cerebral Palsy? Available at: https://www.cdc.gov/ncbddd/cp/facts.html (Accessed: September 2025).
  3. Graham HK, et alNat Rev Dis Primers. 2016;2:15082.
  4. Makki D, et al. J Child Orthop. 2014;8(3):215–219.
  5. Arnould C, et al. Front Neurol. 2014;4;5:48.
  6. Abdel-Hamid HZ. Cerebral Palsy Clinical Presentation. Available at: https://emedicine.medscape.com/article/1179555-clinical#b3 (Accessed: September 2025).
  7. Skalsky AJ and MacDonald CM. Phys Med Rehabil Clin N Am. 2012;23:675–687.
  8. Pandey K. Spasticity Clinical Presentation. Available at: https://emedicine.medscape.com/article/2207448-clinical (Accessed: September 2025).
  9. Hoare B, et al. BMC Neurol. 2010;10:58.
  10. Lidman GRM, et al. Dev Med Child Neurol. 2020;62(2):252–258.

For further information, please refer to the Prescribing Information or the Summary of Product Characteristics.

To access relevant information about Paediatric Spasticity, please choose one of the following options:

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.